[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351944-105":59,"doc-detail-351944-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ongoing-and-completed-clinical-trials-on-prostate-cancer-screening-using-mri","Ongoing and completed clinical trials on prostate cancer screening using MRI","","Evidence reviews and synthesizes findings from ongoing and completed clinical trials evaluating prostate cancer screening strategies that use MRI. It explains how PSA-based testing followed by systematic biopsy historically reduced mortality but carried substantial harms from overdiagnosis. Diagnostic and randomized evidence indicates MRI is sensitive for clinically significant cancer yet less sensitive for low-grade disease, supporting its use as a triage before biopsy. Sequential and PSA-triggered MRI pathways reduce MRI scans, biopsies, and low-grade diagnoses while preserving detection of aggressive cancers, improving the benefit–harm balance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ongoing-and-completed-clinical-trials-on-prostate-cancer-screening-using-mri/351944/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ongoing-and-completed-clinical-trials-on-prostate-cancer-screening-using-mri/351944.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why did prostate MRI replace PSA-only screening in many study strategies?","Question",{"text":112,"@type":113},"PSA testing with systematic biopsy reduced prostate cancer mortality but was limited by substantial overdiagnosis. MRI offers a more precise screening tool to better target clinically significant cancers and reduce unnecessary procedures.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does MRI perform for clinically significant versus low-grade prostate cancer?",{"text":117,"@type":113},"Across diagnostic studies, MRI shows high sensitivity for clinically significant prostate cancer and low sensitivity for low-grade cancer, making it suitable as a prebiopsy triage filter.",{"name":119,"@type":110,"acceptedAnswer":120},"What do randomized trial pathways aim to improve in screening?",{"text":121,"@type":113},"MRI-based pathways aim to lower low-grade cancer detection and biopsy rates while maintaining detection of clinically significant prostate cancer, improving the benefit–harm balance for population screening.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351944,1790784276,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Wallström et al. European Radiology (2026) 36:6476–6486  \n[https://doi.org/10.1007/s00330-026-12533-4](https://doi.org/10.1007/s00330-026-12533-4)  \nSPECIAL REPORT Open Access  \nOngoing and completed clinical trials on prostate cancer screening using MRI  \nJonas Wallström 1,2* , Fredrik Jäderling3,4, Fredrik Langkilde 1,2, Rebecka Arnsrud Godtman5,6, Ola Bratt5,6 and Erik Thimansson7,8  \nAbstract  \nBefore the introduction of prostate MRI, prostate cancer screening relied on prostate-speciﬁc antigen (PSA) testing followed by a systematic biopsy. Although this approach reduced prostate cancer mortality in large, randomized screening trials, its net beneﬁt was questionable because of substantial overdiagnosis. In response, more precise screening tools have been developed. Diagnostic studies demonstrate that MRI has a high sensitivity for clinically signiﬁcant prostate cancer and a low sensitivity for low-grade cancer, making it well-suited as a triage before biopsy. Using MRI as the primary screening test increases detection of potentially clinically signiﬁcant cancer, while sequential strategies—such as those used in the STHLM3-MRI trial—reduce the number of MRI scans, unnecessary biopsies and low-grade cancer diagnoses with maintained detection of clinically signiﬁcant cancer. Several ongoing randomized trials now incorporate PSA-triggered MRI in repeated screening rounds. The Gothenburg 2 trial has reported that its MRI-targeted biopsy pathway halves low-grade cancer detection but misses a few clinically signiﬁcant cancers. Proscreen evaluates a screening pathway with an ancillary kallikrein test to select men for MRI, PROBASE start age 45 years, and large-scale initiatives—such as organized prostate cancer testing (OPT) programs—evaluate real-world feasibility. Key challenges include optimizing MRI protocols, improving consistency in image interpretation, and reducing false-positive ﬁndings, particularly in younger men. Centralized reading, AI support, and reﬁned risk stratiﬁcation may enhance scalability. Accumulating evidence from ongoing trials and population-based programs suggests that MRI-based screening strategies improve the beneﬁt-to-harm ratio in prostate cancer screening.  \nKey Points  \nQuestion This special report summarizes the evidence from ongoing and completed clinical trials on prostate cancer screening using MRI.  \nFindings Across diagnostic and randomized screening trials, MRI-based pathways reduce low-grade cancer detection and biopsy rates while maintaining detection of clinically signiﬁcant prostate cancer.  \nClinical relevance MRI-based screening improves the beneﬁt–harm balance by avoiding unnecessary biopsies andoverdiagnosis while maintaining early detection of aggressive prostate cancer, enabling safer, more precise population-level screening for men.  \nKeywords Magnetic resonance imaging, Mass screening, Prostatic neoplasms  \nIntroduction  \nBefore the era of magnetic resonance imaging (MRI), prostate cancer screening relied on prostate-speciﬁc antigen  \n*Correspondence: Jonas Wallström  \n[Jonas.wallstrom@gu.se](Jonas.wallstrom@gu.se)  \nFull list of author information is available at the end of the article  \n(PSA) testing followed by systematic biopsies [1]. If the PSA value exceeded a threshold, usually 3 ng/mL, the prostate was systematically sampled with 10–12 transrectal ultrasound (TRUS)-guided biopsy cores distributed throughout the gland. This “blind” approach led to both underdiagnosis of randomly missed important cancers and overdiagnosis  \n© The Author(s) 2026 . Open Access This article is licensed under a Creative Commons Attribution 4 . 0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in ","cbCaiazYep61Obhd","https://ap.wps.com/l/cbCaiazYep61Obhd","pdf",2962479,11,"English","# Abstract\n# Key Points\n# Introduction\n## PSA-based screening and systematic biopsy\n## Motivation for MRI-based screening","[{\"question\":\"Why did prostate MRI replace PSA-only screening in many study strategies?\",\"answer\":\"PSA testing with systematic biopsy reduced prostate cancer mortality but was limited by substantial overdiagnosis. MRI offers a more precise screening tool to better target clinically significant cancers and reduce unnecessary procedures.\"},{\"question\":\"How does MRI perform for clinically significant versus low-grade prostate cancer?\",\"answer\":\"Across diagnostic studies, MRI shows high sensitivity for clinically significant prostate cancer and low sensitivity for low-grade cancer, making it suitable as a prebiopsy triage filter.\"},{\"question\":\"What do randomized trial pathways aim to improve in screening?\",\"answer\":\"MRI-based pathways aim to lower low-grade cancer detection and biopsy rates while maintaining detection of clinically significant prostate cancer, improving the benefit–harm balance for population screening.\"}]","Ongoing and completed clinical trials on prostate cancer screening using MRI | PDF",1790096560,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8c550c541754e3248635bfbfd37b53f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd820b4d9c4307f0deba118b9035b1f8.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be21094861627c378f8d1f3259e1ceeb.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1292ca1681fb6e602e4b43b7573e3531.webp",980,1301]